NCT00397982 2017-06-09
Mel47
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
4 trialsNCT01390818 2017-03-07
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
EMD Serono
Phase 1 Completed
NCT00281957 2014-05-20
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01166126 2014-05-15
Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
National Cancer Institute (NCI)
Phase 2 Terminated